The Chairman’s Perspective
By Aldo Del Col, Co-founder & Chairman of the Board, Myeloma Canada
" Myeloma Canada’s goal is to provide support for the Canadian myeloma community, regardless of geography."
Myeloma Canada Launches a Virtual Support Group for Young Patients and Caregivers
Myeloma Canada is pleased to announce the official launch of a virtual support group on Facebook for young patients and caregivers impacted by myeloma.
Learn About the Latest Updates to
Myeloma Canada Research Network Clinical Trials
MCRN 003 - KCd Trial

Carfilzomib (Kyprolis ®)

This is a Phase II single arm study to evaluate the safety and efficacy of once-a-week carfilzomib (Kyprolis ® ) dosing (versus the current twice-weekly dosing schedule) in combination with cyclophosphamide and dexamethasone (KCd)

MCRN 004 - LAURENTIANS Trial

Daratumumab (Darzalex ®)

This MCRN clinical trial will not only provide access to daratumumab (Darzalex®) for eligible patients participating in the trial across the country, but it will also answer the question of how to optimize the use of expensive drug combinations using a cost-effective approach.
MCRN 005 - BOSTON Trial

Selinexor

This pivotal trial will compare the combination of selinexor, bortezomib (Velcade®) and dexamethasone (SVd) versus the combination bortezomib and dexamethasone (Vd) in patients with relapsed or refractory myeloma who have had 1-3 prior lines of therapy.
Spotlight on David McConkey: Living Remotely with Myeloma
My past routine reluctantly had me going off the island once per month. This new weekly routine involves about six hours of travel each way, including a ferry crossing and a road trip, a 10 km round trip walk for my intravenous treatment in a hospital setting for two consecutive days, three out of four weeks per month.”
Upcoming Events

Gatineau, QC
February 24, 2018

*French InfoSession
Bilingual Q&A period


Sudbury, ON
March 10, 2018

*English InfoSession



Moncton, NB
March 24, 2018

*English InfoSession



Register now for the 2018 Myeloma Canada National Conference!
Vancouver, BC
May 12-13, 2018
Radisson Hotel Vancouver Airport

This two-day conference is an opportunity to get the latest news in myeloma research, treatments and disease management. This must-attend conference will include workshops, as well as informative presentations given by leading myeloma experts and an opportunity to meet and exchange with other patients, caregivers and health care professionals.
Save the Date!
Myeloma Canada Charity Golf Classic
Montreal, QC
May 31, 2018
Summerlea Golf & Country Club

**Online booking as of March 15, 2018**
Pre-sale package is now available by contacting Michelle Oana. Contact information below.
Mark your calendars for Myeloma Canada’s Charity Golf Classic being held just a short 20-minute drive from the Dorval airport at Summerlea, the prestigious private golf and country club. Enjoy a full day of golf with complimentary BBQ lunch and on-cart refreshments, as well as a reception cocktail, dinner with entertainment and a silent auction in the evening. A dinner-only option will also be available. Pre-sale golf packages are now available and it’s all for a good cause! Click here for details.
 
 
Get your company involved! Sponsorship packages are now available. For details, please contact Michelle Oana, Associate Director of Development and Communications at moana@myeloma.ca or 514-421-2242.
Community Awards

Myeloma Canada is pleased to announce the winners of the 2017 Community Awards for members across Canada. Find out more on the individuals who have made significant contributions to the Canadian myeloma community in 2017.
Dr Andrew Belch: Celebrating the Retirement of a Leading Canadian Myeloma Researcher

By Lorelei Dalrymple, Chair of the Myeloma Canada Patient Advisory Council
In the Community
Find out what’s happening in the Canadian Myeloma community this winter.
Advocacy Matters
On October 3, Myeloma Canada Patient Advocates from across the country gathered together on Parliament Hill to meet one-on-one with Members of Parliament to not only increase awareness about myeloma at the national level and the express the need to fund important research, but also to stress the importance of improving the Canadian regulatory drug review process and affordability of new therapies, so that Canadians impacted by myeloma are able to access these new, life-saving treatments in a timely manner.
 
As a follow-up to this important day, a number of letters were sent to the Minister of Health by the government representatives that we met with. Click here for an example of the response received from the Minister of Health, Ginette Petitpas Taylor.
 
Myeloma Canada and patient advocates will continue to advocate on behalf Canadians in 2018 to ensure myeloma patients gain access to newest and most innovative therapies.
Reduce Taxes and Leave a Lasting Gift to the Myeloma Community
A donation not only supports Myeloma Canada’s mission and helps raise awareness of this debilitating disease, it can also provide financial benefits.

Did you know? 
Depending on the amount of your donation, you may be able to claim a federal and provincial or territorial non-refundable tax credit of up to 48% when you file your return.

There are a number of tax-effective ways you can support us: